Cardiology Today's Intervention top articles posted in July

Cardiology Today’s Intervention compiled a list of the top 5 stories posted to Healio.com/Intervention in July.

This month, readers were interested in P CI with complete revascularization vs. CABG , updated guidelines for manag ing valvular heart disease, the impact of diabetes in patients undergoing endovascular treatment for peripheral artery disease, and much more.

PCI with complete revascularization yields similar survival to CABG

PCI with complete revascularization yields similar outcomes to CABG, according to newly published data.

In a pooled analysis of data from the SYNTAX, PRECOMBAT and BEST trials, researchers reported a higher risk for the primary endpoint of all-cause death in patients undergoing PCI with incomplete revascularization vs. those undergoing CABG with complete revascularization.

ACC, AHA update guidelines on management of valvular heart disease

The American College of Cardiology and the American Heart Association have released updated recommendations on the treatment of patients with valvular heart disease to reflect the latest research published since the 2014 guidelines.

Diabetes increases risk for amputation, death after endovascular treatment for PAD

Patients with diabetes and symptomatic PAD have a higher risk for major amputation and all-cause death at 12 months after endovascular revascularization, especially among those with critical limb ischemia, according to data published in the Journal of Endovascular Therapy.

3-D printed heart valves show promise for TAVR

Heart valve models created with advanced 3-D printers could soon assist interventional cardiologists, according to a new report published in JACC: Cardiovascular Imaging.

New data from a proof-of-concept study showed that 3-D printed tissue-mimicking phantom materials can be used to develop a procedure simulation platform for in vitro transcatheter aortic valve replacement.

Rivaroxaban, warfarin yield similar outcomes after peripheral artery procedures

The use of rivaroxaban or warfarin after endovascular or open peripheral artery procedures may confer similar safety and efficacy outcomes.